Your browser is no longer supported. Please, upgrade your browser.
Settings
RXDX [NASD]
Prometheus Biosciences, Inc.
Index- P/E- EPS (ttm)- Insider Own13.10% Shs Outstand38.77M Perf Week-7.27%
Market Cap839.84M Forward P/E- EPS next Y-2.07 Insider Trans125.23% Shs Float25.32M Perf Month20.46%
Income- PEG- EPS next Q-0.39 Inst Own67.70% Short Float1.18% Perf Quarter-15.26%
Sales1.23M P/S683.35 EPS this Y-86.10% Inst Trans- Short Ratio1.39 Perf Half Y-
Book/sh7.74 P/B2.77 EPS next Y0.00% ROA- Target Price32.25 Perf Year-
Cash/sh7.94 P/C2.70 EPS next 5Y- ROE- 52W Range16.11 - 30.62 Perf YTD-15.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.01% Beta-
Dividend %- Quick Ratio36.30 Sales past 5Y- Gross Margin- 52W Low33.02% ATR1.74
Employees33 Current Ratio36.30 Sales Q/Q- Oper. Margin- RSI (14)49.81 Volatility5.94% 10.50%
OptionableNo Debt/Eq0.02 EPS Q/Q- Profit Margin- Rel Volume0.48 Prev Close21.26
ShortableYes LT Debt/Eq0.02 EarningsMay 13 AMC Payout- Avg Volume215.53K Price21.43
Recom1.20 SMA204.09% SMA50-1.46% SMA200-0.60% Volume102,408 Change0.80%
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-06-21Initiated SVB Leerink Outperform $34
Apr-06-21Initiated Stifel Buy $25
Apr-06-21Initiated Guggenheim Buy $40
Apr-06-21Initiated Credit Suisse Outperform $30
May-25-21 04:05PM  
May-17-21 08:00AM  
May-14-21 04:01PM  
May-13-21 04:01PM  
Apr-07-21 10:34AM  
Mar-16-21 04:05PM  
Mar-11-21 10:26PM  
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Point72 Biotech Private InvestFormer 10% OwnerMar 16Buy19.00800,00015,200,0002,648,024Mar 17 07:47 PM
PERCEPTIVE ADVISORS LLC10% OwnerMar 16Buy19.00850,00016,150,0003,314,032Mar 16 08:30 PM
Stenhouse MarkChief Operating OfficerMar 16Buy19.0014,000266,00014,000Mar 16 09:49 PM
PAPA JOSEPH CDirectorMar 16Buy19.0015,000285,00015,000Mar 16 09:48 PM
Adams Helen C.DirectorMar 16Buy19.005009,500500Mar 16 09:47 PM
RTW INVESTMENTS, LP10% OwnerMar 16Buy19.00800,00015,200,000800,000Mar 16 07:57 PM
Cormorant Asset Management, LPFormer 10% OwnerMar 16Buy19.00375,0007,125,0002,223,022Mar 18 04:43 PM